Tito Roccia

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, María‐Victoria Mateos, Yaël C. Cohen et al. · Blood · 2022 · 201 citations · Full text

Medicine, Hematology, Oncology +17

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison, Tamia Nguyen, Marzia Rahman et al. · Blood · 2023 · 97 citations

Medicine, Hematology, Oncology +12

Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan

Barbara Cappelli, Robert Chiesa, Costanza Evangelio et al. · British Journal of Haematology · 2009 · 46 citations

Medicine, Hematology, Pharmacotherapy +9

Unpredictability of Intravenous Busulfan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation for Advanced Beta Thalassemia: Limited Toxicity with a Dose-Adjustment Policy

Robert Chiesa, Barbara Cappelli, Roberto Crocchiolo et al. · Biology of Blood and Marrow Transplantation · 2009 · 38 citations · Full text

Pharmacy, Hematology, Pharmacokinetics +15

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengaß, Adam D. Cohen, Mounzer Agha et al. · Blood · 2023 · 29 citations

Medicine, Hematology, Pharmacology +14